📊 TRDA Key Takeaways
Is Entrada Therapeutics, Inc. (TRDA) a Good Investment?
Entrada Therapeutics exhibits severe operational deterioration with revenue collapsing 87.9% YoY to just $25.4M while burning $128.5M in operating cash flow, indicating fundamental business model failure. Although the balance sheet remains intact with $90.4M cash and no debt, the unsustainable burn rate ($129.6M FCF negative) combined with negative 621% operating margins suggests cash runway constraints within 12-18 months without major strategic inflection.
Why Buy Entrada Therapeutics, Inc. Stock? TRDA Key Strengths
- Strong balance sheet with $306.1M stockholders equity and zero long-term debt
- Excellent liquidity position with 12.53x current ratio and $90.4M cash reserves
- No immediate debt maturity risk or covenant concerns
TRDA Stock Risks: Entrada Therapeutics, Inc. Investment Risks
- Catastrophic 87.9% YoY revenue decline indicating failed commercialization or loss of major revenue stream
- Unsustainable cash burn of $128.5M in operating cash flow with only $25.4M in revenue
- Persistent operating losses of $157.9M with -621% operating margin suggesting inability to reach profitability in near-term
- Cash runway of approximately 8 quarters at current burn rate before balance sheet depletion
Key Metrics to Watch
- Quarterly revenue trends and pipeline catalysts - monitor for stabilization or inflection points
- Monthly cash burn rate and operating cash flow - critical for assessing runway extension
- Cost reduction initiatives and R&D spending - assess management's response to revenue collapse
Entrada Therapeutics, Inc. (TRDA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 12.53x current ratio provides a solid financial cushion.
TRDA Profit Margin, ROE & Profitability Analysis
TRDA vs Healthcare Sector: How Entrada Therapeutics, Inc. Compares
How Entrada Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Entrada Therapeutics, Inc. Stock Overvalued? TRDA Valuation Analysis 2026
Based on fundamental analysis, Entrada Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Entrada Therapeutics, Inc. Balance Sheet: TRDA Debt, Cash & Liquidity
TRDA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Entrada Therapeutics, Inc.'s revenue has grown significantly by 63% over the 5-year period, indicating strong business expansion. The most recent EPS of $1.68 reflects profitable operations.
TRDA Revenue Growth, EPS Growth & YoY Performance
TRDA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.6M | -$14.0M | $-0.35 |
| Q2 2025 | $2.0M | -$17.3M | $-1.04 |
| Q1 2025 | $20.6M | -$17.3M | $-0.42 |
| Q3 2024 | $19.6M | $2.9M | $0.08 |
| Q2 2024 | $18.2M | -$6.7M | $-0.78 |
| Q1 2024 | $25.3M | -$6.7M | $-0.21 |
| Q3 2023 | N/A | $2.9M | $0.08 |
| Q2 2023 | N/A | -$6.7M | $-0.74 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Entrada Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
TRDA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Entrada Therapeutics, Inc. (CIK: 0001689375)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 2, 2026 | 4 | xslF345X06/wk-form4_1775162353.xml | View → |
| Mar 11, 2026 | 4 | xslF345X05/wk-form4_1773261310.xml | View → |
| Mar 11, 2026 | 4 | xslF345X05/wk-form4_1773261246.xml | View → |
| Mar 6, 2026 | 4 | xslF345X05/wk-form4_1772833002.xml | View → |
| Mar 3, 2026 | 4 | xslF345X05/wk-form4_1772580082.xml | View → |
❓ Frequently Asked Questions about TRDA
What is the AI rating for TRDA?
Entrada Therapeutics, Inc. (TRDA) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TRDA's key strengths?
Claude: Strong balance sheet with $306.1M stockholders equity and zero long-term debt. Excellent liquidity position with 12.53x current ratio and $90.4M cash reserves.
What are the risks of investing in TRDA?
Claude: Catastrophic 87.9% YoY revenue decline indicating failed commercialization or loss of major revenue stream. Unsustainable cash burn of $128.5M in operating cash flow with only $25.4M in revenue.
What is TRDA's revenue and growth?
Entrada Therapeutics, Inc. reported revenue of $25.4M.
Does TRDA pay dividends?
Entrada Therapeutics, Inc. does not currently pay dividends.
Where can I find TRDA SEC filings?
Official SEC filings for Entrada Therapeutics, Inc. (CIK: 0001689375) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TRDA's EPS?
Entrada Therapeutics, Inc. has a diluted EPS of $-3.47.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TRDA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Entrada Therapeutics, Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TRDA stock overvalued or undervalued?
Valuation metrics for TRDA: ROE of -47.0% (sector avg: 15%), net margin of -565.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TRDA stock in 2026?
Our dual AI analysis gives Entrada Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TRDA's free cash flow?
Entrada Therapeutics, Inc.'s operating cash flow is $-128.5M, with capital expenditures of $1.0M. FCF margin is -509.6%.
How does TRDA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -565.5% (avg: 12%), ROE -47.0% (avg: 15%), current ratio 12.53 (avg: 2).